InsomniaNCT05408013
The Prevalence of Insomnia in Patients With Psychiatric Disorders
An observational study of Insomnia, run by University of Bern at 1 site in Switzerland.
Trial summary
The primary aim of the proposed project is to investigate the prevalence of insomnia in patients with psychiatric disorders treated as inpatients in psychiatric hospitals in two study sites in Switzerland and nine study sites in Germany. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Insomnia
- How many people
- 427 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jul 2021to 31 Mar 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who suffer from a psychiatric disorder according to the DSM-5 and who are currently treated as inpatients in a psychiatric hospital
Who may be able to join
- patients who suffer from a psychiatric disorder according to the DSM-5 and who are currently treated as inpatients in one of these psychiatric hospitals:
- 2 swiss study sites: Universitäre Psychiatrische Dienste in Bern, Privatklinik Meiringen.
- 9 german study sites: Freiburg, Ingolsatdt, Kiel, Klingenmünster, Leipzig, Mannheim, Nürnberg, Paderborn, Regensburg
Who cannot join
- Age under 18 years
- involuntary stay at the clinic
- unable to give informed consent
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Universitäre Psychiatrische Dienste Bern (Upd)
Bern, Canton of Bern, 3000 60
About this study
The primary aim of the proposed project is to investigate the prevalence of insomnia in patients with psychiatric disorders treated as inpatients in psychiatric hospitals in two study sites in Switzerland and nine study sites in Germany. The secondary aim is to investigate whether there are demographic or disorder specific parameters that influence the prevalence of insomnia in patients with psychiatric disorders.
Read the detailed description
QUALITY ASSURANCE PLAN \& SOURCE DATA VERIFICATION
For quality assurance the Ethics Committee may visit the research sites. For each study participant, a paper based case report form (CRF) will be maintained. CRFs will be kept current to reflect subject status at each phase during the course of study. Data for statistical analysis will be stored in an electronic database. Data will be transferred manually from the paper CRF to the electronic data base. As for the paper based CRF, the data stored electronically will not contain any personal information by which the participant can be identified. Only trained project personnel will be authorized for entries into the electronic database and authorized persons will be identifiable for every entry they made. Routinely collected data during daily clinical practice will be transferred to the participant CRF (e.g. diagnoses and medication).
DATA DICTIONARY
BASEC, Business Administration System for Ethical Committees CRF, Case report form FOPH, Federal Office of Public Health HRA, Human Research Act HRO, Ordinance on Human
STANDARD OPERATING PROCEDURE The recruitment of the study participants is consecutive. In all study sites, all newly admitted patients will be registered on a list each day. This list will be available for the study physicians. From this list, patients who are visibly not eligible (involuntary stay, under custody) will be deleted. Depending on the capacities of the study physicians, within three days after admission, 1-15 patients will be selected from the patients remaining on the list per day. The selected patients will be asked whether they agree to participate in the study.
The overall project duration will be 12 months starting the 1st of July 2021 until the end of June 2022. The patients will be screened according to the inclusion and exclusion criteria. The study investigator will then hold one session of 20 to 60 minutes with each participant filling out the following questionnaires:
- The study information and the informed consent
- The informed consent about the further use of the patient data
- Demographic data and general patient documentations
- PSQI: Pittsburgh sleep quality index
- ISI: Insomnia severity index
- The Epworth Sleepiness Scale
- SF-12: Short form 12 questionnaire about the subjective health status
- PHQ-9: Patient health questionnaire 9
- Fatigue Severity Screening
Participants will be withdrawn from the study immediately if there are any concerns about the participants' safety. Participants can also choose to withdraw from the study at any time, and are not required to provide their reason for withdrawing from the study. Coded data acquired before withdrawal will be analyzed as described in the participant information sheet.
If a serious event occurs, the research project will be interrupted and the Ethics Committee notified on the circumstances via BASEC within 7 days according to HRO Art. 21 .
SAMPLE SIZE ASSESSMENT \& STATISTICAL ANALYSIS PLAN
In Table 1 in the study protocol which is attached in the documents section, the 95%- confidence intervals for prevalence in the range from 15% (p=0.15) to 25% (p=0.25) can be seen for sample sizes of n= 200, n= 250, n=300 and n= 500 patients. In consideration of the accuracy of the estimation of varying prevalence, the planned study aims to investigate 500 psychiatric inpatients. The named sample size will be sufficient to estimate prevalence rates with sufficient power.
PLAN FOR MISSING DATA Dropouts will be replaced by recruitment of new participants until the target sample size has been achieved.
- Conditions
- Insomnia
- Medical subject headings
- Sleep Initiation and Maintenance Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| ward patients in psychiatric hospitals | Patients in psychiatric hospitals will be assessed so that the prevalence of insomnia in psychiatric inpatients can be estimated. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Insomnia Disorder
The prevalence of insomnia disorder will be assessed at a one-time point per patient during a study session with a clinician.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jun 2022
- Study start1 Jul 2021
- Primary completion31 Mar 2025
- Study completion31 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for InsomniaStudies of the same condition, open and under way.
- More trials run by University of BernThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 427 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Bern
- Sponsor type
- University, hospital or other
- Collaborators
- University Hospital Freiburg, Universitätsklinikum Schleswig-Holstein Klinik für Psychiatrie und Psychotherapie, Schlafzentrum Pfalzklinikum Klingenmünster, Klinik und Poliklinik für Psychiatrie und Psychotherapie Leipzig, Zentralinstitut für Seelische Gesundheit Mannheim, Privatklinik Meiringen, Universitätsklinik für Psychiatrie und Psychotherapie, PMU Nürnberg, LWL-Klinik Paderborn, Klinik für Psychiatrie und Psychotherapie der Universität Regensburg, Kompetenzzentrum Schlafmedizin Charité - Campus Benjamin Franklin, Klinikum Ingolstadt (withdrawal of participation)
- Responsible party
- Principal investigator, Christoph Nissen, University of Bern
- Investigators
- Christoph Nissen, Prof. Dr. med, Principal investigator, Sleep Research in Psychiatry
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05408013
- Sponsor's protocol ID
- (ID 2020-01992)
- Status last verified
- Mar 2026
- First submitted
- 28 Oct 2021
- Last updated
- 3 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Participant data that underlie the results reported in the future article after deidentification will be shared.
Publications
Seow LSE, Verma SK, Mok YM, Kumar S, Chang S, Satghare P, Hombali A, Vaingankar J, Chong SA, Subramaniam M. Evaluating DSM-5 Insomnia Disorder and the Treatment of Sleep Problems in a Psychiatric Population. J Clin Sleep Med. 2018 Feb 15;14(2):237-244. doi: 10.5664/jcsm.6942.
PubMed 29394962
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Prevalence of Insomnia in Patients With Psychiatric Disorders
- ClinicalTrials.gov ID
- NCT05408013
- Acronym / sponsor ID
- (ID 2020-01992)
- Conditions
- Insomnia
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 427 participants (actual)
- Lead sponsor
- University of BernUniversity, hospital or other
- Collaborators
- University Hospital Freiburg, Universitätsklinikum Schleswig-Holstein Klinik für Psychiatrie und Psychotherapie, Schlafzentrum Pfalzklinikum Klingenmünster, Klinik und Poliklinik für Psychiatrie und Psychotherapie Leipzig, Zentralinstitut für Seelische Gesundheit Mannheim, Privatklinik Meiringen, Universitätsklinik für Psychiatrie und Psychotherapie, PMU Nürnberg, LWL-Klinik Paderborn, Klinik für Psychiatrie und Psychotherapie der Universität Regensburg, Kompetenzzentrum Schlafmedizin Charité - Campus Benjamin Franklin, Klinikum Ingolstadt (withdrawal of participation)
- Study start
- 1 Jul 2021 (actual)
- Primary completion
- 31 Mar 2025 (actual)
- Study completion
- 31 Mar 2025 (actual)
- First posted
- 7 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary aim of the proposed project is to investigate the prevalence of insomnia in patients with psychiatric disorders treated as inpatients in psychiatric hospitals in two study sites in Switzerland and nine study sites in Germany. The secondary aim is to investigate whether there are demographic or disorder specific parameters that influence the prevalence of insomnia in patients with psychiatric disorders.
Detailed description
QUALITY ASSURANCE PLAN \& SOURCE DATA VERIFICATION
For quality assurance the Ethics Committee may visit the research sites. For each study participant, a paper based case report form (CRF) will be maintained. CRFs will be kept current to reflect subject status at each phase during the course of study. Data for statistical analysis will be stored in an electronic database. Data will be transferred manually from the paper CRF to the electronic data base. As for the paper based CRF, the data stored electronically will not contain any personal information by which the participant can be identified. Only trained project personnel will be authorized for entries into the electronic database and authorized persons will be identifiable for every entry they made. Routinely collected data during daily clinical practice will be transferred to the participant CRF (e.g. diagnoses and medication).
DATA DICTIONARY
BASEC, Business Administration System for Ethical Committees CRF, Case report form FOPH, Federal Office of Public Health HRA, Human Research Act HRO, Ordinance on Human
STANDARD OPERATING PROCEDURE The recruitment of the study participants is consecutive. In all study sites, all newly admitted patients will be registered on a list each day. This list will be available for the study physicians. From this list, patients who are visibly not eligible (involuntary stay, under custody) will be deleted. Depending on the capacities of the study physicians, within three days after admission, 1-15 patients will be selected from the patients remaining on the list per day. The selected patients will be asked whether they agree to participate in the study.
The overall project duration will be 12 months starting the 1st of July 2021 until the end of June 2022. The patients will be screened according to the inclusion and exclusion criteria. The study investigator will then hold one session of 20 to 60 minutes with each participant filling out the following questionnaires:
- The study information and the informed consent
- The informed consent about the further use of the patient data
- Demographic data and general patient documentations
- PSQI: Pittsburgh sleep quality index
- ISI: Insomnia severity index
- The Epworth Sleepiness Scale
- SF-12: Short form 12 questionnaire about the subjective health status
- PHQ-9: Patient health questionnaire 9
- Fatigue Severity Screening
Participants will be withdrawn from the study immediately if there are any concerns about the participants' safety. Participants can also choose to withdraw from the study at any time, and are not required to provide their reason for withdrawing from the study. Coded data acquired before withdrawal will be analyzed as described in the participant information sheet.
If a serious event occurs, the research project will be interrupted and the Ethics Committee notified on the circumstances via BASEC within 7 days according to HRO Art. 21 .
SAMPLE SIZE ASSESSMENT \& STATISTICAL ANALYSIS PLAN
In Table 1 in the study protocol which is attached in the documents section, the 95%- confidence intervals for prevalence in the range from 15% (p=0.15) to 25% (p=0.25) can be seen for sample sizes of n= 200, n= 250, n=300 and n= 500 patients. In consideration of the accuracy of the estimation of varying prevalence, the planned study aims to investigate 500 psychiatric inpatients. The named sample size will be sufficient to estimate prevalence rates with sufficient power.
PLAN FOR MISSING DATA Dropouts will be replaced by recruitment of new participants until the target sample size has been achieved.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| ward patients in psychiatric hospitals | – | –Patients in psychiatric hospitals will be assessed so that the prevalence of insomnia in psychiatric inpatients can be estimated. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who suffer from a psychiatric disorder according to the DSM-5 and who are currently treated as inpatients in a psychiatric hospital
Key inclusion criteria (3 listed)
- patients who suffer from a psychiatric disorder according to the DSM-5 and who are currently treated as inpatients in one of these psychiatric hospitals:
- 2 swiss study sites: Universitäre Psychiatrische Dienste in Bern, Privatklinik Meiringen.
- 9 german study sites: Freiburg, Ingolsatdt, Kiel, Klingenmünster, Leipzig, Mannheim, Nürnberg, Paderborn, Regensburg
Key exclusion criteria (3 listed)
- Age under 18 years
- involuntary stay at the clinic
- unable to give informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Insomnia Disorder
Time frame: Day 1
The prevalence of insomnia disorder will be assessed at a one-time point per patient during a study session with a clinician.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2026.
- Background: PubMed 29394962Seow LSE, Verma SK, Mok YM, Kumar S, Chang S, Satghare P, Hombali A, Vaingankar J, Chong SA, Subramaniam M. Evaluating DSM-5 Insomnia Disorder and the Treatment of Sleep Problems in a Psychiatric Population. J Clin Sleep Med. 2018 Feb 15;14(2):237-244. doi: 10.5664/jcsm.6942.
- Individual participant dataSharing planned: Yes. Participant data that underlie the results reported in the future article after deidentification will be shared.
Related trials for Insomnia
Recruiting
Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness
Nocturia, Insomnia
Not yet recruiting
A Transdiagnostic Sleep Health Intervention for Veterans With PTSD
Stress Disorders, Post-Traumatic, Sleep Initiation and Maintenance Disorders
Recruiting
Effect of Cyclic Sighing Breathing Exercise on CRBD, Pain, and Sleep Quality in Patients Undergoing TUR
Transurethral Resection of Bladder Tumor, Transurethral Resection of the Prostate (TURP)
Recruiting
Evaluation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in Individuals With Mild Traumatic Brain Injury (mTBI)
Sleep Architecture, Mild Traumatic Brain Injury
RecruitingPhase 3
A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the Day
Insomia Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christoph Nissen, Prof. Dr. med principal investigator
Sleep Research in Psychiatry
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Insomnia, run by University of Bern at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Insomnia Disorder (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05408013, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2026.